651 related articles for article (PubMed ID: 29301757)
1. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
[TBL] [Abstract][Full Text] [Related]
2. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ;
N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124
[TBL] [Abstract][Full Text] [Related]
3. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension.
Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber MA; Jamerson KA
Am J Hypertens; 2021 May; 34(5):531-539. PubMed ID: 33216879
[TBL] [Abstract][Full Text] [Related]
5. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
[TBL] [Abstract][Full Text] [Related]
6. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
[TBL] [Abstract][Full Text] [Related]
7. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
Bakris GL; Toto RD; McCullough PA; Rocha R; Purkayastha D; Davis P;
Kidney Int; 2008 Jun; 73(11):1303-9. PubMed ID: 18354383
[TBL] [Abstract][Full Text] [Related]
8. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
[TBL] [Abstract][Full Text] [Related]
9. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group.
Frishman WH; RAM CV; McMahon FG; Chrysant SG; Graff A; Kupiec JW; Hsu H
J Clin Pharmacol; 1995 Nov; 35(11):1060-6. PubMed ID: 8626878
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular events during differing hypertension therapies in patients with diabetes.
Weber MA; Bakris GL; Jamerson K; Weir M; Kjeldsen SE; Devereux RB; Velazquez EJ; Dahlöf B; Kelly RY; Hua TA; Hester A; Pitt B;
J Am Coll Cardiol; 2010 Jun; 56(1):77-85. PubMed ID: 20620720
[TBL] [Abstract][Full Text] [Related]
11. Renal outcomes in hypertensive Black patients at high cardiovascular risk.
Weir MR; Bakris GL; Weber MA; Dahlof B; Devereux RB; Kjeldsen SE; Pitt B; Wright JT; Kelly RY; Hua TA; Hester RA; Velazquez E; Jamerson KA
Kidney Int; 2012 Mar; 81(6):568-76. PubMed ID: 22189843
[TBL] [Abstract][Full Text] [Related]
12. [Is the combination of benazepril and amlodipine more effective in hypertension than the combination of benazepril and hydrochlorothiazide? Results of the ACCOMPLISH trial].
Preobrazhenskiĭ DV
Kardiologiia; 2009; 49(2):81-2. PubMed ID: 19254225
[No Abstract] [Full Text] [Related]
13. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
Waeber B; Aschwanden R; Sadecky L; Ferber P
J Hypertens; 2001 Nov; 19(11):2097-104. PubMed ID: 11677377
[TBL] [Abstract][Full Text] [Related]
14. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with amlodipine/benazapril (CCB/ACEI) superior to hydrochlorothiazide/benazapril in high-risk hypertensive patients.
Cardiovasc J Afr; 2008; 19(3):163. PubMed ID: 18568181
[No Abstract] [Full Text] [Related]
16. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Julius S; Kjeldsen SE; Weber M; Brunner HR; Ekman S; Hansson L; Hua T; Laragh J; McInnes GT; Mitchell L; Plat F; Schork A; Smith B; Zanchetti A;
Lancet; 2004 Jun; 363(9426):2022-31. PubMed ID: 15207952
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study].
Fan CM; Yan LR; Tao YK; Wang L; Li YQ; Gao MM; Wang YN; Li CX; Wang XW; Lu XL; Pang HM; Li YS
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jan; 39(1):57-60. PubMed ID: 21418799
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension.
Reichek N; Devereux RB; Rocha RA; Hilkert R; Hall D; Purkayastha D; Pitt B
Hypertension; 2009 Oct; 54(4):731-7. PubMed ID: 19687350
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control.
Jamerson KA; Devereux R; Bakris GL; Dahlöf B; Pitt B; Velazquez EJ; Weir M; Kelly RY; Hua TA; Hester A; Weber MA
Hypertension; 2011 Feb; 57(2):174-9. PubMed ID: 21189401
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure.
Mohler ER; Herrington D; Ouyang P; Mangano C; Ritter S; Davis P; Purkayastha D; Gatlin M; Vogel RA;
J Clin Hypertens (Greenwich); 2006 Oct; 8(10):692-8. PubMed ID: 17028482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
